Mizagliflozin, a selective SGLT1 inhibitor, improves vascular cognitive impairment in a mouse model of small vessel disease

Abstract

Previously, we showed that sodium/glucose cotransporter 1 (SGLT1) participates in vascular cognitive impairment in small vessel disease. We hypothesized that SGLT1 inhibitors can improve the small vessel disease induced‐vascular cognitive impairment. We examined the effects of mizagliflozin, a selective SGLT1 inhibitor, and phlorizin, a non‐selective SGLT inhibitor, on vascular cognitive impairment in a mouse model of small vessel disease. Small vessel disease was created using a mouse model of asymmetric common carotid artery surgery (ACAS). Two and/or 4 weeks after ACAS, all experiments were performed. Cerebral blood flow (CBF) was decreased in ACAS compared with sham‐operated mice. Phlorizin but not mizagliflozin reversed the decreased CBF of ACAS mice. Both mizagliflozin and phlorizin reversed the ACAS‐induced decrease in the latency to fall in a wire hang test of ACAS mice. Moreover, they reversed the ACAS‐induced longer escape latencies in the Morris water maze test of ACAS mice. ACAS increased SGLT1 and proinflammatory cytokine gene expressions in mouse brains and phlorizin but not mizagliflozin normalized all gene expressions in ACAS mice. Hematoxylin/eosin staining demonstrated that they inhibited pyknotic cell death in the ACAS mouse hippocampus. In PC12HS cells, IL‐1β increased SGLT1 expression and decreased survival rates of cells. Both mizagliflozin and phlorizin increased the survival rates of IL‐1β‐treated PC12HS cells. These results suggest that mizagliflozin and phlorizin can improve vascular cognitive impairment through the inhibition of neural SGLT1 and phlorizin also does so through the improvement of CBF in a mouse model of small vessel disease.

Hyperglycemic exacerbation of myocardial infarction through SGLT1 - a glucose paradox

“…In the absence of demonstrable SGLT2 expression within the heart, the high 1μmol/L canagliflozin can be expected to be mediating its protective effect against high glucose mediated injury via myocardial SGLT1 inhibition. However, to further demonstrate the importance of SGLT1, we tested a specific SGLT1 inhibitor, Mizagliflozin which has an IC 50 of 166nmol/L in rat 26 and a Ki of 27.0nmol/L and 8170nmol/L for SGLT1 and SGLT2 respectively from in-vitro human studies 27 . 100nmol/L mizagliflozin will inhibit SGLT1 specifically, and in doing so, we hypothesised that it would completely abrogate glucose-mediated excess injury.…”

Effect and Mechanism of Yisui Fuyongtang (YSFYT) Decoction on Cognitive Function and Synaptic Plasticity in Rats with Vascular Cognitive Impairment

“…The hippocampus lies between the cerebral thalamus and the medial temporal lobe. As a part of the limbic system, it is the most sensitive cerebral region of rats to ischemia and hypoxia [34,35]. Furthermore, this organizational structure is intimately correlated to the storage of memory information and learning functions.…”

The sodium-glucose cotransporter isoform 1 as a target for influence in type 2 diabetes: basic physiology and functional properties in the light of evidence-based facts

“…В данном исследовании микрососудистые нарушения были смоделированы хирургическим путём, после чего в группе вмешательства в течение 30-42 дней осуществлялось подкожное введение мизаглифлозина. В результате было зарегистрировано улучшение не только мозгового кровотока, но ещё и когнитивных функций, оценённых с помощью тестов на координацию и логику для мышей [11].…”